These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9561111)

  • 41. Myocardial protection by the leukotriene synthesis inhibitor BAY X1005: importance of transcellular biosynthesis of cysteinyl-leukotrienes.
    Rossoni G; Sala A; Berti F; Testa T; Buccellati C; Molta C; Muller-Peddinghaus R; Maclouf J; Folco GC
    J Pharmacol Exp Ther; 1996 Jan; 276(1):335-41. PubMed ID: 8558451
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inhibition of leukotriene biosynthesis improves renal function in experimental glomerulonephritis.
    Petric R; Ford-Hutchinson A
    J Lipid Mediat Cell Signal; 1995 May; 11(3):231-40. PubMed ID: 7551679
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cysteinyl leukotrienes and leukotriene B mediate vasoconstriction to arginine vasopressin in rat basilar artery.
    Trandafir CC; Nishihashi T; Ji X; Wang A; Kurahashi K
    Clin Exp Pharmacol Physiol; 2005 Dec; 32(12):1027-33. PubMed ID: 16445567
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chemistry and structure--activity relationships of leukotriene receptor antagonists.
    Bernstein PR
    Am J Respir Crit Care Med; 1998 Jun; 157(6 Pt 2):S220-5; discussion S225-6, S247-8. PubMed ID: 9647603
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Requirement of free arachidonic acid for leukotriene B4 biosynthesis by 12-hydroperoxyeicosatetraenoic acid-stimulated neutrophils.
    Kanaji K; Okuma M; Sugiyama T; Sensaki S; Ushikubi F; Uchino H
    Biochem Biophys Res Commun; 1986 Jul; 138(2):589-95. PubMed ID: 3017333
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Benzothiazole hydroxy ureas as inhibitors of 5-lipoxygenase: use of the hydroxyurea moiety as a replacement for hydroxamic acid.
    Greco MN; Hageman WE; Powell ET; Tighe JJ; Persico FJ
    J Med Chem; 1992 Aug; 35(17):3180-3. PubMed ID: 1324317
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Potential phospholipid source(s) of arachidonate used for the synthesis of leukotrienes by the human neutrophil.
    Chilton FH
    Biochem J; 1989 Mar; 258(2):327-33. PubMed ID: 2539804
    [TBL] [Abstract][Full Text] [Related]  

  • 48. P2X7 receptor activation in rat brain cultured astrocytes increases the biosynthetic release of cysteinyl leukotrienes.
    Ballerini P; Ciccarelli R; Caciagli F; Rathbone MP; Werstiuk ES; Traversa U; Buccella S; Giuliani P; Jang S; Nargi E; Visini D; Santavenere C; Di Iorio P
    Int J Immunopathol Pharmacol; 2005; 18(3):417-30. PubMed ID: 16164825
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of a 5-lipoxygenase inhibitor and leukotriene antagonist (PF 5901) on antigen-induced airway responses in neonatally immunized rabbits.
    Herd CM; Donigi-Gale D; Shoupe TS; Burroughs DA; Yeadon M; Page CP
    Br J Pharmacol; 1994 May; 112(1):292-8. PubMed ID: 8032653
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A prodrug of a 2,6-disubstituted 4-(2-arylethenyl)phenol is a selective and orally active 5-lipoxygenase inhibitor.
    Farina PR; Graham AG; Homon CA; Lazer ES; Hattox SE; Riska PS; Gundel RH; Wegner CD
    J Pharmacol Exp Ther; 1993 May; 265(2):483-9. PubMed ID: 8388452
    [TBL] [Abstract][Full Text] [Related]  

  • 51. BRP-187: A potent inhibitor of leukotriene biosynthesis that acts through impeding the dynamic 5-lipoxygenase/5-lipoxygenase-activating protein (FLAP) complex assembly.
    Garscha U; Voelker S; Pace S; Gerstmeier J; Emini B; Liening S; Rossi A; Weinigel C; Rummler S; Schubert US; Scriba GK; Çelikoğlu E; Çalışkan B; Banoglu E; Sautebin L; Werz O
    Biochem Pharmacol; 2016 Nov; 119():17-26. PubMed ID: 27592027
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Arachidonic acid activates phospholipase D in human neutrophils; essential role of endogenous leukotriene B4 and inhibition by adenosine A2A receptor engagement.
    Grenier S; Flamand N; Pelletier J; Naccache PH; Borgeat P; Bourgoin SG
    J Leukoc Biol; 2003 Apr; 73(4):530-9. PubMed ID: 12660228
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Leukotriene A4 modulates generation of leukotriene B4 and sulphidopeptide leukotrienes by human neutrophils.
    Hilger RA; König W
    Immunology; 1992 Nov; 77(3):408-15. PubMed ID: 1335961
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Furo(2,3-c)quinolines and furo(3,4-c)quinolones--synthesis and investigation of lipoxygenase inhibition].
    Görlitzer K; Fabian J; Jones PG; Frohberg P; Drutkowski G
    Pharmazie; 2002 Mar; 57(3):159-68. PubMed ID: 11933842
    [No Abstract]   [Full Text] [Related]  

  • 55. Structure-activity relationships leading to WAY-121,520, a tris aryl-type, indomethacin-based, phospholipase A2 (PLA2)/leukotriene biosynthesis inhibitor.
    Kreft A; Nelson J; Musser J; Failli A; Shah U; Kubrak D; Banker A; Steffan R; Schiehser G; Sturm R
    Agents Actions; 1993; 39 Spec No():C33-5. PubMed ID: 8273578
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Morphological and functional changes of coronary vasculature caused by transcellular biosynthesis of sulfidopeptide leukotrienes in isolated heart of rabbit.
    Sala A; Aliev GM; Rossoni G; Berti F; Buccellati C; Burnstock G; Folco G; Maclouf J
    Blood; 1996 Mar; 87(5):1824-32. PubMed ID: 8634429
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics and pharmacodynamics of fenleuton, a 5-lipoxygenase inhibitor, in ponies.
    Marr K; Marsh K; Hernandez L; Cunningham FM; Lees P
    Res Vet Sci; 1998; 64(2):111-7. PubMed ID: 9625466
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Leukotriene B4 biosynthesis in polymorphonuclear leukocytes from blood of umbilical cord, infants, children, and adults.
    Kikawa Y; Shigematsu Y; Sudo M
    Pediatr Res; 1986 May; 20(5):402-6. PubMed ID: 3012451
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Metabolism of arachidonic acid by human neutrophils. Characterization of the enzymatic reactions that lead to the synthesis of leukotriene B4.
    Sun FF; McGuire JC
    Biochim Biophys Acta; 1984 Jun; 794(1):56-64. PubMed ID: 6329309
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics, safety, and ability to diminish leukotriene synthesis by zileuton, an inhibitor of 5-lipoxygenase.
    Rubin P; Dubé L; Braeckman R; Swanson L; Hansen R; Albert D; Carter G
    Agents Actions Suppl; 1991; 35():103-16. PubMed ID: 1781415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.